ClinicalTrials.gg
RecruitingNCT06930352Updated Nov 9, 2026

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

A Phase 2 interventional study of Biospecimen Collection and Bone Marrow Aspiration in Acute Myeloid Leukemia, sponsored by Uma Borate. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Uma Borate · Phase 2, Interventional, and Treatment

How we know

Updated Nov 9, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies testing ziftomenib in Leukemia, Myeloid, Acute — 8 open to participants now, 11 under way, 1 of them phase 3. ziftomenib · Leukemia, Myeloid, Acute.

Planned enrollment
5th of 11
70 · median 44
Started
2027
the only one that year
Phase 2
2 of 11
1 open now
Primary completion
2028-01
later than 5 of 10 live
Registered
6th of 11
by date
Lead sponsor
1 of 11
Uma Borate

Among the 11 studies testing ziftomenib in Leukemia, Myeloid, Acute, this one is the 5th largest by planned enrollment, is the only one that started in 2027, is one of 2 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 6th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

8 of the 11 studies testing ziftomenib in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ziftomenib

ziftomenib: first FDA approval 2025 (KOMZIFTI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ziftomenib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This phase II trial tests how well ziftomenib works in treating patients with NPM1 mutated or KMT2A rearranged acute myeloid leukemia (AML) and are not eligible to receive standard therapy. AML is often due to genetic changes in the cancer cells, including mutations in the NPM1 gene and rearrangements involving the KMT2A gene. These mutations result in activation of the menin pathway. Menin is a type of protein in the body that helps to regulate some of the naturally occurring processes in the body, but can also be involved in some types of cancers. Ziftomenib blocks this menin pathway and may prevent the cancer cells from continuing to grow. Giving ziftomenib may kill more cancer cells in patients with NPM1 mutated or KMT2A rearranged AML that are not eligible to receive standard therapy.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine the efficacy of ziftomenib in treatment-naïve patients with KMT2A-rearranged (r) and NPM1-mutated (m) AML who are not candidates for standard therapy, with primary endpoint of complete remission (CR) + CR/response with hematologic improvement (CRh), assessed after 6 cycles of treatment using the best response achieved in that time.

SECONDARY OBJECTIVES:

I. To determine rates of transfusion independence for 8- and 16-week periods. II. To determine response including CR, composite CR (CRc) (CR + CRh + CR with incomplete blood count recovery [CRi] + CR with incomplete platelet recovery [CRp]), proportion of patients achieving CRc with negative measurable residual disease (MRD), overall response rate (ORR) (CRc + partial response [PR] + morphologic leukemia free state [MLFS]).

III. To determine duration of response (DOR). IV. To determine overall survival (OS), and event free survival (EFS) at 24 months.

V. To evaluate if ziftomenib treatment improves quality of life using the Patient Reported Outcomes Measurement Information System (PROMIS)-29+2 version (v) 2.1 questionnaire.

VI. To assess safety in this patient population by determining the number of patients experiencing adverse events/serious adverse events.

EXPLORATORY OBJECTIVES:

I. To assess efficacy in patients with mutations thought to be sensitive to menin inhibition, other than KMT2A rearrangements and NPM1 mutations.

II. To perform measurable residual disease (MRD) monitoring via liquid biopsy to monitor clonal dynamics during treatment.

III. To assess the clonal, biochemical and differentiation changes in AML cells during treatment with menin inhibition using flow cytometry, cytogenetics and serial next generation sequencing on bone marrow specimens before and during treatment to assess for potential resistance mutations or clonal evolution that may be predictors of relapse.

OUTLINE:

Patients receive ziftomenib orally (PO) once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo cytoreduction therapy with hydroxyurea up to end of cycle 1, cytarabine within 7 days of starting treatment, or leukapheresis within 7 days of treatment to reduce white blood cell count to =\< 10,000/uL. Additionally, patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) at screening and bone marrow biopsy and/or aspiration and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 6 months for up to 24 months.

03

Conditions studied

  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study
  • Morphologically confirmed diagnosis of the following based on 2022 World Health Organization (WHO) Classification:

    • Treatment-naïve acute myeloid leukemia
    • KMT2A rearrangement (defined as KMT2A translocations) OR NPM1 mutation (defined as NPM1 mutation resulting in cytoplasmic localization, or NPM1c) OR other mutations that have been shown to exhibit sensitivity to menin inhibition. Mutation status will be known from initial diagnosis using standard of care testing, which can be performed locally
  • Patients ineligible or unwilling to receive standard of care induction therapy, such as 7+3, hypomethylating agent, venetoclax, or other standard of care (SOC) regimens with ineligibility defined by the following:

    • ≥ 75 years of age with both of the following;

      • Subject must have adequate renal function as demonstrated by a ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24-hours urine collection
      • Subject must have adequate liver function as demonstrated by (AST) ≤ 3.0 x (ULN) and alanine aminotransferase (ALT) ≤ 3.0 x ULN (unless considered due to leukemic organ involvement) OR
    • ≥ 18 to 74 years of age with at least one of the following co-morbidities:

      • (ECOG) performance status of 2 or 3;
      • Cardiac history of congestive heart failure (CHF) requiring treatment or ≤ 50% or chronic stable angina;
      • Diffusion capacity of the lung for carbon monoxide (DLCO) ≤ 65% or (FEV1) ≤ 65%;
      • Creatinine clearance ≥ 30 mL/min to \< 45 ml/min;
      • Moderate hepatic impairment with total > 1.5 to ≤ 3.0 x ULN;
      • Venous thromboembolism benefitting from prolonged anticoagulation or presence of prosthetic heart valve or any indication for therapeutic anticoagulation with a single agent
      • Prior history of severe infection requiring hospitalization with risk of recurrence with subsequent
      • Any other comorbidity that the physician judges to be incompatible with standard frontline therapy must be reviewed and approved by the study team before study enrollment
  • Peripheral white blood cell (WBC) counts ≤ 10,000/uL. Patients may receive hydroxyurea, cytarabine, or leukapheresis to control and maintain white blood cell count until the end of cycle 1
  • Women of must be willing to use a highly effective method of throughout the study and for at least 180 days after the last dose of study treatment
  • Non-sterile male patients must agree to use a highly effective method of contraception with partner(s) throughout the study and for at least 90 days after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia
  • Diagnosis of chronic myelogenous leukemia in blast crisis
  • Clinically active central nervous system (CNS) leukemia
  • Prior treatment for AML except for hydroxyurea and/or cytarabine used for control of leukocytosis
  • Treatment with concomitant drugs that are strong inhibitors or inducers of cytochrome P450-isozyme 3A4 () with the exception of antibiotics, antifungals, and antivirals that are used as standard of care or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient
  • Detectable viral load for , , or surface antigen indicative of active infection. Patients with controlled disease will not be excluded from study enrollment
  • Pre-existing disorder predisposing the patient to a serious or life-threatening infection (e.g. cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias not related to AML)
  • Active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection
  • Mean Fridericia's formula- interval (QTcF) > 480 ms on triplicate (ECG)
  • Any psychiatric illness that prevents patient from process
  • Women who are pregnant or lactating. All female patients with must have a negative serum pregnancy test within 72 hours prior to starting treatment
  • Participants requiring dual antiplatelet therapy
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Treatment (ziftomenib)

    Patients receive ziftomenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo cytoreduction therapy with hydroxyurea up to end of cycle 1, cytarabine within 7 days of starting treatment, or leukapheresis within 7 days of treatment to reduce white blood cell count to =\< 10,000/uL. Additionally, patients undergo ECHO or MUGA at screening and bone marrow biopsy and/or aspiration and blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Procedure: Echocardiography Test · Drug: Hydroxyurea · Procedure: Leukapheresis · Procedure: Multigated Acquisition Scan · Other: Questionnaire Administration · Drug: Ziftomenib

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow biopsy and/or aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy and/or aspiration

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • Given cytarabine

    Also known as: .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • Given hydroxyurea

    Also known as: Droxia, Hydrea, Hydroxycarbamide, Litalir, Onco-Carbide, Oncocarbide, Oxeron, SQ 1089, SQ-1089, Syrea, WR 83799

  • ProcedureLeukapheresis

    Undergo leukapheresis

    Also known as: Leukocyte Adsorptive Apheresis, Leukocytopheresis, Therapeutic Leukopheresis, White Blood Cell Reduction Apheresis

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • OtherQuestionnaire Administration

    Ancillary studies

  • Given PO

    Also known as: KO 539, KO-539, KO539, Menin-KMT2A Inhibitor KO 539, Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor KO 539, Menin-MLL Inhibitor KO-539, Menin-MLL Interaction Inhibitor KO 539

06

What researchers measure

Primary outcomes

  1. Complete remission (CR) plus CR/response with hematologic improvement

    Will be assessed after 6 cycles of treatment using the best response achieved in that time. Will be calculated in each arm for the efficacy analysis population and reported along with two-sided 95% exact binomial confidence limits, in a modified intent-to-treat analysis.

    Time frame: After 6 cycles of treatment (cycle length = 28 days)

Secondary outcomes

  1. Rate of transfusion independence

    Transfusion independence is defined as the proportion of subjects without transfusions during any consecutive 8 weeks (56 days) starting from Study Day 1 and has correlated with palliative benefits in patients with AML \[19\]. The major criteria for judging response will include physical examination and laboratory evaluation.

    Time frame: Up to 24 months

  2. CR rate

    Will also be calculated in the primary efficacy analysis cohort along with 95% exact binomial confidence intervals.

    Time frame: Up to 24 months

  3. Composite CR (CRc) rate

    Will also be calculated in the primary efficacy analysis cohort along with 95% exact binomial confidence intervals.

    Time frame: Up to 24 months

  4. CRc with negative measurable residual disease

    Will also be calculated in the primary efficacy analysis cohort along with 95% exact binomial confidence intervals.

    Time frame: Up to 24 months

  5. Overall response rate

    Will also be calculated in the primary efficacy analysis cohort along with 95% exact binomial confidence intervals.

    Time frame: Up to 24 months

  6. Duration of response

    Will be estimated using the method of Kaplan-Meier and calculated in the primary efficacy analysis.

    Time frame: From the date first achieved response to the date of progression or relapse or death, whichever occurs first, assessed up to 24 months

  7. Overall survival

    Will be estimated using the method of Kaplan-Meier and calculated in the primary efficacy analysis.

    Time frame: From date of treatment start to death due to all causes, assessed up to 24 months

  8. Event free survival

    Will be estimated using the method of Kaplan-Meier and calculated in the primary efficacy analysis.

    Time frame: From initiation of study treatment to the date of confirmed progressive disease, confirmed morphological relapse, treatment failure after 6 cycles of study treatment (cycle length = 28 days) or death from any cause, assessed up to 24 months

  9. Changes in quality of life

    Will be measured using Patient Reported Outcomes Measurement Information System (PROMIS) 29 +2 version (v) 2.1 and Patient Reported Outcomes (PRO) Common Terminology Criteria for Adverse Events (CTCAE). The raw sum will be calculated and converted to the standardized T score. Descriptive statistics will be used to present the PROMIS and PRO-CTCAE scores at each time point, and we will also use graphical display to visualize the change in quality of life over time. Wilcoxon signed rank test will be used to test if the change over time is statistically significant. To further quantify the change over time, linear mixed model will be fit for PROMIS score and PRO-CTCAE score, and if the sample size allows, the model will control for important clinical covariates as well.

    Time frame: Day 1 of each cycle up to completion of treatment (cycle length = 28 days)

  10. Incidence of adverse events (AEs)

    AEs will be graded according to CTCAE v 5.0. The toxicity data captured will include type, frequency, grade, severity, timing of onset, duration, and relationship to study drug. Frequency tables will be used to summarize the AE data, where the number of patients with different types of AE will be tabulated by toxicity grade, counting only the highest grade of a certain type of AE occurred to the same patient. All adverse events regardless of attribution as well as those treatment-related AEs will be summarized.

    Time frame: Up to 30 days after last dose of study treatment

07

Study locations

1 of 1 sites recruiting
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Recruiting
    • Uma M. Borate, MBBS, MD, MSc · ContactUma.Borate@osumc.edu · 614-685-9828
    • Uma M. Borate, MBBS, MD, MSc · Principal investigator
08

References and documents

Related links

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 12 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Oct 2026 → Jan 2027, primary completion Dec 2027 → Jan 2028 and completion Dec 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 16, 2025
StartEst.
Jan 15, 2027was Oct 2026
Primary completionEst.
Jan 31, 2028was Dec 2027
CompletionEst.
Jan 31, 2028was Dec 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 15, 2027
Nov 9, 2026
Primary completion
Dec 31, 2027→Jan 31, 2028
Nov 9, 2026
Study completion
Dec 31, 2027→Jan 31, 2028
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Oct 1, 2026→Jan 15, 2027
    Primary completion Dec 31, 2027→Jan 31, 2028
    Study completion Dec 31, 2027→Jan 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06930352
Lead sponsor
Uma Borate
Collaborators
Kura Oncology, Inc.
Responsible party
Uma Borate (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Apr 16, 2025
Start date
Jan 15, 2027 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Ohio State University Comprehensive Cancer Center
Contact
OSUCCCclinicaltrials@osumc.edu
800-293-5066
Uma M Borate, MBBS, MD, MSc
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziftomenib

Start the discussion